儿科药物基因组学检测的临床实施策略
本文综述儿科药物基因组学(PGx)检测的临床实施问题。文章讨论PGx对儿科用药安全与疗效的意义,分析来自加拿大、荷兰和英国的实践案例,并指出高质量儿科PGx证据获取困难、需合理外推成人数据,未来需加强国际协作与教育以推动实施。
要点
- 儿科PGx检测可提升用药安全、改善疗效或降低毒性风险。
- 儿科PGx证据获取困难,常需在科学合理前提下外推成人研究数据。
- 国际跨学科协作与儿科PGx教育是推动实施的关键。
核心结论
- 在儿科实施PGx检测有望提高药物安全性、改善疗效或降低毒性风险。
- 目前儿科PGx检测的临床实施仍不均衡且有限。
- 提升儿科PGx检测临床效用与成本效益的证据基础对推动实施至关重要。
研究设计与样本
- 本文为综述,讨论PGx对儿科的意义并从儿童健康视角考虑实施策略。
- 文中提供来自加拿大、荷兰和英国的实施案例,并考虑不同医疗体系及其不同实施路径。
主要发现
- 与多数儿科药理学研究一样,获取高质量PGx证据存在公认障碍,尤其当患者数量较少时。
- 儿科超说明书或未获批用药仍广泛存在。
- 仅纳入少量儿童的试验单独很少能提供足以改变临床实践的PGx证据。
临床怎么用
- 在科学合理的前提下,可从较大规模成人PGx研究外推数据以支持儿科实践。
- 应基于加拿大、荷兰和英国等地的实施经验制定未来推荐。
- PGx联盟与儿科临床研究网络将继续在高效开发有效实施策略中发挥核心作用。
局限性
- 儿科患者数量可能较少,获取高质量PGx证据存在公认障碍。
- 仅纳入少量儿童的试验单独很少能提供足以改变临床实践的PGx证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacogenomics (PGx) relates to the study of genetic factors determining variability in drug response. Implementing PGx testing in paediatric patients can enhance drug safety, helping to improve drug efficacy or reduce the risk of toxicity. Despite its clinical relevance, the implementation of PGx testing in paediatric practice to date has been variable and limited. As with most paediatric pharmacological studies, there are well-recognised barriers to obtaining high-quality PGx evidence, particularly when patient numbers may be small, and off-label or unlicensed prescribing remains widespread. Furthermore, trials enrolling small numbers of children can rarely, in isolation, provide sufficient PGx evidence to change clinical practice, so extrapolation from larger PGx studies in adult patients, where scientifically sound, is essential. This review paper discusses the relevance of PGx to paediatrics and considers implementation strategies from a child health perspective. Examples are provided from Canada, the Netherlands and the UK, with consideration of the different healthcare systems and their distinct approaches to implementation, followed by future recommendations based on these cumulative experiences. Improving the evidence base demonstrating the clinical utility and cost-effectiveness of paediatric PGx testing will be critical to drive implementation forwards. International, interdisciplinary collaborations will enhance paediatric data collation, interpretation and evidence curation, while also supporting dedicated paediatric PGx educational initiatives. PGx consortia and paediatric clinical research networks will continue to play a central role in the streamlined development of effective PGx implementation strategies to help optimise paediatric pharmacotherapy.
引用
- Barker CIS, Groeneweg G, Maitland-van der Zee AH, et al. Pharmacogenomic testing in paediatrics: Clinical implementation strategies. Br J Clin Pharmacol. 2022. PMID: 34907575. doi:10.1111/bcp.15181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。